RNA interference: A potent tool for gene-specific therapeutics

American Journal of Transplantation

Volumn 4, Issue 8, 2004, Pages 1227-1236

  Ichim, Thomas E ^a,b   Li, Mu ^a,b   Qian, Hua ^a,b   Popov, Igor A ^a,b   Rycerz, Katarzyna ^a   Zheng, Xiufen ^a   White, David ^a,b,c,d   Zhong, Robert ^a,b,c,d   Min, Wei Ping ^a,b,c,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Gene silencing; Gene therapy; RNA interference; Transplantation

Indexed keywords

ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; DOUBLE STRANDED RNA; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; LIPOSOME; MESSENGER RNA; PLASMID DNA; PROTEIN; PROTEIN BCL 2; RNA POLYMERASE; SMALL INTERFERING RNA; STAT4 PROTEIN; TARGET OF RAPAMYCIN KINASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; CANCER; EXPRESSION VECTOR; GENE SILENCING; GENE THERAPY; GENETIC MANIPULATION; GRAFT SURVIVAL; HEPATITIS; IMMUNOMODULATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RNA INTERFERENCE; RNA SYNTHESIS; RNA TRANSCRIPTION; SHORT SURVEY; VIRUS INFECTION;

ANIMALS; GENE SILENCING; GENE THERAPY; GENETIC TECHNIQUES; GENETIC VECTORS; HEPATITIS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUSES;

EID: 3543009635     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00530.x     Document Type: Short Survey

References (103)

1. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA Interference. biology, mechanism, and applications. Microbiol Mol Biol Rev 2003; 67: 657-685.
2. Davidson BL. Hepatic diseases - hitting the target with inhibitory RNAs. N Engl J Med 2003; 349: 2357-2359.
3. Wall NR, Shi Y. Small RNA: can RNA interference be exploited for therapy? Lancet 2003; 362: 1401-1403.
4. Ullu E, Djikeng A, Shi H, Tschudi C. RNA interference: advances and questions. Philos Trans R Soc Lond B Biol Sci 2002; 357: 65-70.
5. Jorgensen RA, Cluster PD, English J, Que Q, Napoli CA. Chalcone synthase cosuppression phenotypes in petunia flowers: comparison of sense vs. antisense constructs and single-copy vs. complex T-DNA sequences. Plant Mol Biol 1996; 31: 957-973.
6. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
7. Proud CG. PKR: a new name and new roles. Trends Biochem Sci 1995; 20: 241-246.
8. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003; 4: 457-467.
9. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res 2002; 30: 1757-1766.
10. Caplen NJ, Mousses S. Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann N Y Acad Sci 2003; 1002: 56-62.
11. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
12. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A 2003; 100: 1844-1848.
13. Hara K, Maruki Y, Long X et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177.
14. Ji J, Wernli M, Klimkait T, Erb P. Enhanced gene silencing by the application of multiple specific small interfering RNAS. FEBS Lett 2003; 552: 247-252.
15. Katoh T, Susa M, Suzuki T, Umeda N, Watanabe K. Simple and rapid synthesis of siRNA derived from in vitro transcribed shRNA. Nucleic Acids Res Suppl 2003: 249-250.
16. Milligan JF, Groebe DR, Witherell GW, Uhlenbeck OC. Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res 1987; 15: 8783-8798.
17. Amarasinghe AK, Calin-Jageman I, Harmouch A, Sun W, Nicholson AW. Escherichia coli ribonuclease III. affinity purification of hexahistidine-tagged enzyme and assays for substrate binding and cleavage. Methods Enzymol 2001; 342: 143-158.
18. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004; 22: 321-325.
19. Kawasaki H, Suyama E, Iyo M, Taira K. siRNAs generated by recombinant human Dicer induce specific and significant but target site-independent gene silencing in human cells. Nucleic Acids Res 2003; 31: 981-987.
20. Myers JW, Jones JT, Meyer T, Ferrell JE Jr. Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing. Nat Biotechnol 2003; 21: 324-328.
21. Tuschl T. Expanding small RNA interference. Nat Biotechnol 2002; 20: 446-448.
22. Kobayashi N, Matsui Y, Kawase A et al. Vector-based in vivo RNA interference: dose- and time-dependent suppression of transgene expression. J Pharmacol Exp Ther 2003; 308: 688-693.
23. Czauderna F, Santel A, Hinz M et al. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 2003; 31: e127.
24. Castanotto D, Li H, Rossi JJ. Functional siRNA expression from transfected PCR products. RNA 2002; 8: 1454-1460.
25. Zheng L, Liu J, Batalov S et al. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci U S A 2004; 101: 135-140.
26. Surowiak P. Evaluation of transfection effectiveness using fluorescein-labelled oligonucleotides and various liposomes. Folia Morphol (Warsz) 2003; 62: 397.
27. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418: 38-39.
28. Zhang X, Shan P, Jiang D et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 2003; 279: 10677-10684.
29. Barton GM, Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci U S A 2002; 99: 14943-14945.
30. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006-1010.
31. Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P. Lentiviral-mediated RNA interference. Hum Gene Ther 2002; 13: 2197-2201.
32. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003; 100: 183-188.
33. Lee MT, Coburn GA, McClure MO, Cullen BR. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol 2003; 77: 11964-11972.
34. Hasuwa H, Kaseda K, Einarsdottir T, Okabe M. Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett 2002; 532: 227-230.
35. Reich SJ, Fosnot J, Kuroki A et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-216.
36. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327: 761-766.
37. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003; 8: 769-776.
38. Novina CD, Murray MF, Dykxhoorn DM et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8: 681-686.
39. , Wilson JA, Jayasena S, Khvorova A et al. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci U S A 2003; 100: 2783-2788.
40. Song E, Lee SK, Wang J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351.
41. Zhang R, Guo Z, Lu, J et al. Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA. Chin Med J (Engl) 2003; 116: 1262-1264.
42. Li MJ, Bauer G, Michienzi A et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 2003; 8: 196-206.
43. Randall G, Grakoui A, Rice CM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci U S A 2003; 100: 235-240.
44. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938-5945.
45. McCown M, Diamond MS, Pekosz A, The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 2003; 313: 514-524.
46. Kawasaki H, Taira K. Short hairpin type of dsRNAs that are controlled by tRNA (Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res 2003; 31: 700-707.
47. Martinez LA, Naguibneva I, Lehrmann H et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A 2002; 99: 14849-14854.
48. Choudhury A, Charo J, Parapuram SK et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004; 108: 71-77.
49. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 2003; 101: 1566-1569.
50. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003; 17: 1713-1721.
51. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003; 9: 1291-1300.
52. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 2003; 22: 5694-5701.
53. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003; 63: 4713-4723.
54. Hill JA, Ichim TE, Kusznieruk KP et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 2003; 171: 691-696.
55. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834-839.
56. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 263-264.
57. Nishiwaki Y, Yokota T, Hiraoka M et al. Introduction of short interfering RNA to silence endogenous E-selectin in vascular endothelium leads to successful inhibition of leukocyte adhesion. Biochem Biophys Res Commun 2003; 310: 1062-1066.
58. Laderach D, Compagno D, Danos O, Vainchenker W, Galy A. RNA interference shows critical requirement for N F-kappa B p50 in the production of IL-12 by human dendritic cells. J Immunol 2003; 171: 1750-1757.
59. Wong AW, Brickey WJ, Taxman DJ et al. CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. Nat Immunol 2003; 4: 891-898.
60. Dumont FJ. Treatment of transplant rejection: are the traditional immunosuppressants good enough? Curr Opin Investig Drugs 2001; 2: 357-363.
61. Billaud EM. Clinical pharmacology of immunosuppressive drugs: year 2000 - time for alternatives. Therapie 2000; 55: 177-183.
62. Wijdenes J, Roy C, Morel-Fourrier B, Racadot E. Monoclonal antibodies in human organ transplantation and auto-immune diseases. Therapie 1992; 47: 283-287.
63. McManus MT, Haines BB, Dillon CP et al. Small interfering RNA-mediated gene silencing in T lymphocytes. J Immunol 2002; 169: 5754-5760.
64. Kojima S, Vignjevic D, Borisy GG. Improved silencing vector coexpressing GFP and small hairpin RNA. Biotechniques 2004; 36: 74-79.
65. Banerjea A, Li MJ, Bauer G et al. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther 2003; 8: 62-71.
66. Li XC, Ima A, Li Y, Zheng XX, Malek TR, Strom TB. Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival. J Immunol 2000; 164: 1193-1199.
67. Nishikomori R, Usui T, Wu CY, Morinobu A, O'Shea JJ, Strober W. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling. J Immunol 2002; 169: 4388-4398.
68. Bishop DK, Chan Wood S, Eichwald EJ, Orosz CG. Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions. J Immunol 2001; 166: 3248-3255.
69. Koglin J, Glysing-Jensen T, Gadiraju S, Russell ME. Attenuated cardiac allograft vasculopathy in mice with targeted deletion of the transcription factor STAT4. Circulation 2000; 101: 1034-1039.
70. Zhou P, Szot GL, Guo Z et al. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol 2000; 165: 5580-5587.
71. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002; 295: 338-342.
72. Liang X, Lu L, Chen Z et al. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation 2003; 76: 721-729.
73. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003; 18: 155-167.
74. Stoll S, Jonuleit H, Schmitt E et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 1998; 28: 3231-3239.
75. Puccetti P, Belladonna ML, Grohmann U. Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity. Crit Rev Immunol 2002; 22: 373-390.
76. Grilley BJ, Gee AP. Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility. Cytotherapy 2003; 5: 197-207.
77. Zender L, Hutker S, Liedtke C et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A 2003; 100: 7797-7802.
78. Vail DM, Kurzman ID, Glawe PC et al. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 2002; 50: 131-136.
79. Rosenthal DI, Yom SS, Liu L et al. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs 2002; 20: 343-349.
80. Park JW, Hong K, Kirpotin DB et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002; 8: 1172-1181.
81. Rodriguez M, Coma S, Noe V, Ciudad CJ. Development and effects of immunoliposomes carrying an antisense oligonucleotide against DHFR RNA and directed toward human breast cancer cells overexpressing HER2. Antisense Nucleic Acid Drug Dev 2002; 12: 311-325.
82. Sioud M, Sorensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 2003; 312: 1220-1225.
83. Mercadal M, Domingo JC, Petriz J, Garcia J, de Madariaga MA. Preparation of immunoliposomes bearing poly (ethylene glycol) - coupled monoclonal antibody linked via a cleavable disulfide bond for ex vivo applications. Biochim Biophys Acta 2000; 1509: 299-310.
84. Zhang YF, Boado RJ, Pardridge WM. Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res 2003; 20: 1779-1785.
85. Phillips NC, Gagne L, Tsoukas C, Dahman J. Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status. J Immunol 1994; 152: 3168-3174.
86. Steinman RM, Pack M, Inaba K. Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev 1997; 156: 25-37.
87. Vertut-Doi A, Ishiwata H, Miyajima K. Binding and uptake of liposomes containing a poly (ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774, influence of PEG content and its molecular weight. Biochim Biophys Acta 1996; 1278: 19-28.
88. Menasche P, Termignon JL, Pradier F et al. Experimental evaluation of Celsior, a new heart preservation solution. Eur J Cardiothorac Surg 1994; 8: 207-213.
89. Baker CJ, Longoria J, Gade PV, Starnes VA, Barr ML. Addition of a water-soluble alpha-tocopherol analogue to University of Wisconsin solution improves endothelial viability and decreases lung reperfusion injury. J Surg Res 1999; 86: 145-149.
90. McAnulty JF, Huang XQ. The effect of simple hypothermic preservation with Trolox and ascorbate on lipid peroxidation in dog kidneys. Cryobiology 1996; 33: 217-225.
91. Natori S, Higuchi H, Contreras P, Gores GJ. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Liver Transpl 2003; 9: 278-284.
92. Randsbaek F, Kimose HH, Hansen SB, Jacobsen B, Botker HE, Nielson TT. Captopril improves oxygen and glucose extraction in pig hearts during reperfusion after cold cardioplegic storage. Scand Cardiovasc J 2000; 34: 201-208.
93. Chen W, Bennett CF, Wang ME et al. Perfusion of kidneys with unformulated 'naked' intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury. Transplantation 1999; 68: 880-887.
94. Vos IH, Govers R, Grone HJ et al. NF kappa B decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000; 14: 815-822.
95. Goldberg LC. Pretreatment of kidney allografts with monoclonal antibodies to CD45: results of a multicentre study. CD45 Study Group. Transpl Int 1994; 7 (Suppl 1): S252-S254.
96. Davies JA, Ladomery M, Hohenstein P et al. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wtl tumour suppressor is required for nephron differentiation. Hum Mol Genet 2004; 13: 235-246,
97. Bertrand J, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002; 296: 1000-1004.
98. Celotto AM, Graveley BR. Exon-specific RNAi: a tool for dissecting the functional relevance of alternative splicing. RNA 2002; 8: 718-724.
99. Grishok A, Tabara H, Mello CC. Genetic requirements for inheritance of RNAi in C. elegans. Science 2000; 287: 2494-2497.
100. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
101. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells, Nat Biotechnol 2002; 20: 505-508.
102. Devroe E, Silver PA. Retrovirus-delivered siRNA. BMC Biotechnol 2002; 2: 15.
103. Yang D, Buchholz F, Huang Z et al. Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2002; 99: 9942-9947.